Hoppa till innehål

Technology

Mesenkia’s proof-of-concept studies with KITAIbodies® show strong therapeutic potential. It opens the door to precision therapies engineered at nano-scale — with the potential for global clinical impact. From a single domain (nanobody), we aim to unlock a new generation of targeted cancer treatments. KITAIbodies® is a modular platform that allows us to engineer multiple therapeutics formats from a single validated domain.

The KITAIbodies® hinders tumor growth and invasion via the essential APRIL-HVEM-NFκB axis in the tumor and alleviates immune suppression by blocking the BTLA-HVEM axis on immune cells.

Therapeutic drugs incorporating the KITAIbodies® have a clear potential for integration into both first line therapy and standard of care. KITAIbodies® are developed from the evolutionary unique Alpaca antibodies known for their superior properties and ability to penetrate the tumor.

our-tech-half-media-mesenkia-16-9

Image created in https://BioRender.com

Intellectual Property & Platform Innovation

Mesenkia Therapeutics’ IP portfolio includes biologic drug candidates, primarily targeting the aggressive brain tumor glioblastoma, where HVEM acts as central biological marker and target. Mesenkia has exclusive commercial license for this technology from Tokyo University. The specially designed antibody platform, based on a very solid experimental basis, attacks tumors and inhibits cancer growth in such a way that the cancer cells have difficulty adapting to treatment. As the platform is modular, it can be combined with other pharmaceuticals for constructions, which is already done in partnership. Furthermore, several new drug candidates are currently undergoing experimental verification.

IP01 – PCT/JP2019/051635
Therapeutic and Prophylactic Agent for Glioma, Brain Tumor Malignancy Marker and Brain Tumor Prognostic Marker

IP02 – PCT/JP2024/028824
Novel HVEM Binding Protein and Pharmaceutical Composition Containing Them

Cookiesamtycke

På webbplatsen används nödvändiga kakor för att webbplatsen ska fungera på ett bra sätt. Du kan även välja att samtycka till kakor för statistikinsamling.